Cisplatin can be safely administered to ovarian cancer patients with hypersensitivity to carboplatin

详细信息    查看全文

• 作者：A. Bergamini^a ; ^b ; C. Pisano^a ; M. Di Napoli^a ; L. Arenare^a ; C. Della Pepa^a ; R. Tambaro^a ; G. Facchini^a ; P. Gargiulo^a ; S. Rossetti^a ; G. Mangili^b ; S. Pignata^a ; ^{s.pignata@istitutotumori.na.it} ; S.C. Cecere^a
• 关键词：Ovarian cancer ; Chemotherapy ; Carboplatin ; Cisplatin ; Hypersensitivity reaction ; Adverse drug reaction
• 刊名：Gynecologic Oncology
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：144
• 期：1
• 页码：72-76
• 全文大小：243 K
• 卷排序：144

文摘

HSR are a common adverse event in patients rechallenged with carboplatin for ROC Carboplatin-PLD is associated with a lower risk of developing HSR compared to other doublets Several strategies have been developed to continue platinum-based therapy in these patients. Cisplatin rechallenge in patients with carboplatin HSR is a safe and feasible approach. In patients treated with cisplatin without a carboplatin-related HSR, a low rate of cisplatin-related HSR has been detected.